Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06632860
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-10-07
Brief Title:
A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors
Sponsor:
None
Organization:
None
Study Overview
Official Title:
a Novel Dual-Targeting Molecular Probe TATE-RGD for the Diagnostic Integration of SSTR2 and αvβ3 Positive Tumors
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The US FDA approved a targeted somatostatin receptor 2 imaging agent 68Ga-DOTATATE in 2016 It has higher uptake in small cell lung cancer pulmonary carcinoid and medullary thyroid cancer Integrin αvβ3 is highly expressed in some tumor cells and new blood vessels making it an ideal target for targeted diagnosis and treatment of tumors and tumor vessels68Ga-labeled DOTA-TATE-RGD is a new type of tumor-specific imaging agent developed by researchers based on the above foundation which is used for targeted diagnosis and internal radiation therapy for patients with SSTR2 and αvβ3 positive tumors
Detailed Description:
This research has conducted extensive studies on the treatment of neuroendocrine tumors with 177Lu-EB-TATE and the treatment of FAP-expressing tumors with 177Lu-EB-FAPI The same protocol had demonstrated 68Ga-TATE-RGD showed an increasing TBR suggesting the tracer kinetic advantage of TATE-RGD Compared to the single-target tracer DOTATATE the dual-target TATE-RGD probe has a clear advantage in detecting NETs liver metastases and it can be explored for potential therapeutic uses in future studies and used for related companion diagnostics in targeted radiolabeling therapy RLT which has been published in the 1st-impact factor journal European Journal of Nuclear Medicine and Medical Imaging IF 96 performing a small-dose diagnostic PET imaging with the same tracer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None